Jeff Jacobs, Ph.D.

December 15, 2022

Dr. Jacobs has more than 25 years of experience in drug discovery and target identification, and has led, co-led and mentored multiple discovery programs from concept stage through development candidate nomination, and from investigational new drug enabling studies through to pivotal clinical trials. Dr. Jacobs was most recently Chief Scientific Officer at Goldfinch Bio, where he led the research and discovery program to help build its portfolio of therapeutics for rare kidney diseases. Before Goldfinch, Dr. Jacobs held roles of increasing responsibilities at Ardelyx, Inc., and was promoted to Chief Scientific Officer. During his time at Ardelyx, he led the discovery effort for IBSRELA®, an oral small molecule for the treatment of irritable bowel syndrome with constipation, that became its first U.S. Food and Drug Administration (FDA) approved product. Earlier, Dr. Jacobs held senior roles in development chemistry at Sunesis Pharmaceuticals, along with similar roles leading chemistry teams at Versicor, Inc. (acquired by Pfizer), and Affymax (acquired by Glaxo Wellcome). Dr. Jacobs earned a Ph.D. in bioorganic chemistry from the University of California, Berkeley and a B.S. in chemistry from Gonzaga University.